ARCHIVES

Advanced Ovarian Cancer Responds To Irofulven In Phase II Studies

This article is from The Cancer Letter archive.

Vol. 24 No. 10 | October 26, 2001

Download PDF Visit The Full Archive

Related Articles

Salick Signs contract for Fixed-Price Oncology Services

April 1, 1994

NCI Plans to Expand R01 Grant Funding By$48 Million, Increase Other Grants Also

February 16, 1996

Kimes Calls Headline On DRG ‘Exaggerated Negativity’ In Letter

April 5, 1991

Novartis Begins Study Of Femara And Zometa In Postmenopausal Early Breast Cancer

December 27, 2002

Dinner To Raise Funds For NIH Children’s Inn

March 31, 1989

Only 20% of Doctors Advise CRC According To Guidelines

October 29, 2010